Lilly’s CAR-T devotion; CBER’s next top dog?

<figure><div><img src="https://imgproxy.divecdn.com/8nTrHlsFTcngJswJxr_8afos9dxh_YxQE6LZmgMA2_I/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDkyNDczMjEzX2VHaVhSdTEuanBn.webp"/></div></figure> Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Lilly’s latest CAR-T buyout A push by Eli Lilly to acquire genetic platforms like the multibillion-dollar acquisition of in vivo CAR-T biote...

PharmaVoice Staff · 2026-04-24

Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Lilly’s latest CAR-T buyout A push by Eli Lilly to acquire genetic platforms like the multibillion-dollar acquisition of in vivo CAR-T biote...

Source: PharmaVoice